PubRank

CAR-T Cell Immunotherapy for Advanced Lung Cancer

Clinical Trial ID NCT03330834

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03330834

Top papers

Rank Title Journal Year PubWeight™‹?›
1 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009 77.71
2 The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 24.94
3 Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009 24.11
4 Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011 18.99
5 Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015 12.54
6 Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014 12.00
7 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015 11.98
8 Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015 10.12
9 The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004 9.39
10 Cancer statistics, 1999. CA Cancer J Clin 1999 9.18
11 Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010 9.13
12 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011 8.26
13 Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008 8.17
14 CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013 7.99
15 Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009 6.91
16 Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016 6.84
17 CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011 6.38
18 Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014 5.60
19 Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013 5.43
20 T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2014 5.42
21 Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993 5.23
22 Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A 1989 4.63
23 Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015 4.25
24 Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014 3.94
25 Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011 3.82
26 PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007 3.23
27 Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 2016 3.18
28 The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2004 2.33
29 Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013 1.89
30 MYC regulates the antitumor immune response through CD47 and PD-L1. Science 2016 1.87
31 Adoptive cellular therapy: a race to the finish line. Sci Transl Med 2015 1.82
32 Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol 2015 1.76
33 Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One 2015 1.73
34 Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw 2014 1.71
35 Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol 2015 1.56
36 Manipulating the PD-1 pathway to improve immunity. Curr Opin Immunol 2013 1.21
37 The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol 2014 1.13
38 Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park) 2003 1.06
39 Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity 2016 0.96
40 Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J Thorac Dis 2015 0.87
41 Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncol 2015 0.83
42 Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastases. Cancer Gene Ther 2014 0.83
43 [Advances on driver oncogenes of non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2015 0.80
44 Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods 2016 0.78
45 ErbB-targeted CAR T-cell immunotherapy of cancer. Immunotherapy 2015 0.77
Next 100